Chemoimmunoconjugates for the Treatment of Cancer

Herlyn, 1982, IgG2a monoclonal antibodies inhibit human tumour growth through interactions with effector cells, Proc. Natl. Acad. Sci. U.S.A., 79, 4761, 10.1073/pnas.79.15.4761 Tax, 1981, Monoclonal antibodies against antigens displayed on progressively growing mammary tumor, Proc. Natl. Acad. Sci. U.S.A., 72, 1383 Press, 1991, Immunotoxins, Biotherapy, 3, 65, 10.1007/BF02175100 Koppel, 1990, Recent advances with monoclonal antibody drug targeting for the treatment of human cancer, Bioconj. Chem., 1, 13, 10.1021/bc00001a002 Tazzari, 1989, Targeting of a plasma cell line with a conjugate containing xanthine oxidase and the monoclonal antibody 62B1, Transplantation, 48, 119, 10.1097/00007890-198907000-00028 Obrist, 1982, In vitro effects of antitumor antibody-chemotactic factor complexes, Clin. Immunol. Immunopathol., 25, 91, 10.1016/0090-1229(82)90168-4 LeBerthon, 1990, Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate, Cancer Res., 5, 2694 Britton, 1991, Overview of radioimmunotherapy: A European perspective, Anti. Immunocon. Radiopharm., 4, 133 D.L. Pierce., N.D. Heindel., and K.J. Schray., M.M. Jelter., J.G. Emrich., D.V. Woo., Misonidazole conjugates of the colorectal tumor associated monoclonal antibody 17-1A. Bioconj. Chem. 1: 314-318. S.L. Rakestraw., R.G. Tompkins., M.L. Yarmush., Preparation and characterization of immunoconjugates for antibody-targeted photolysis. Bioconj. Chem. 1: 212-221. Berinstein, 1987, Antibody-directed targeting of liposomes to human cell lines: Role of binding and internalization on growth inhibition, Cancer Res, 47, 5954 Anderson-Berg, 1986, Nucluear magnetic resonance and gamma camera tumor imaging using gadolinium-labeled monoclonal antibodies, J. Nucl. Med., 27, 829 Hayzer, 1991, Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents, Bioconj. Chem., 2, 301, 10.1021/bc00011a002 Paxton, 1992, Carboranyl peptide-antibody conjugates for neutron-capture therapy: Preparation, characterization, and in vivo evaluation, Bioconj. Chem., 3, 241, 10.1021/bc00015a007 Hermentin, 1990, Hinge-thiol coupling of monoclonal antibody to silanized iron oxide particles and evaluation of magnetic cell depletion, Bioconj. Chem., 1, 411, 10.1021/bc00006a007 Midoux, 1992, Activation of mouse macrophages by muramyl dipeptide coupled with antimacrophage monoclonal antibody, Bioconj. Chem., 3, 194, 10.1021/bc00014a016 Trouet, 1972, Chemotherapy through lysosomes with a DNA-daunorubicin complex., Nature (London) New Biol., 239, 110, 10.1038/newbio239110a0 Trouet, 1982, A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: In vitro and in vivo studies, Proc. Natl. Acad. Sci. U.S.A., 79, 626, 10.1073/pnas.79.2.626 Zunino, 1981, Comparison of antitumor effects of daunorubicin covalently linked to poly-l-amino acid carriers, Eur. J. Cancer Clin. Oncol., 20, 421, 10.1016/0277-5379(84)90091-9 Shih, 1991, Anthracycline immunoconjugates prepared by a site specific linkage via an amino-dextran intermediate carrier, Cancer Res., 51, 4192 Yamaguchi, 1979, Preparation of concanavalin A-ricin A-chain conjugate and its biological activity against various cultured cells, J. Natl. Cancer Inst., 62, 1387 Pozansky, 1984, Insulin 18: Carrier potential for enzyme and drug therapy, Science, 223, 1304, 10.1126/science.6367042 Varga, 1977, Melanotropindaunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells., Nature (London), 267, 56, 10.1038/267056a0 Kaneto, 1981, Thyrotropin-daunomycin conjugate shows receptor mediated cytotoxicity in cultured thyroid cells, Horm. Metab. Res., 13, 110, 10.1055/s-2007-1019187 Noda, 1991, Cholesterol sulfate-containing liposome entraping adriamycin-pharmacokinetics and antineoplastic effect, J. Clin. Biochem. Nutri., 10, 181, 10.3164/jcbn.10.181 Zimmerman, 1983, Cellular drug-carrier systems and their possible targeting., 2, 153 Sur, 1983, Effect of liposomal encapsulation of cis-platinum diamminodichloride in the treatment of Ehrlich ascites carcinoma, Oncology, 40, 372, 10.1159/000225765 FitzGerald, 1992, Pseudomonas exotoxin: Recombinant conjugates as therapeutic agents, Biochem. Soc. Trans., 20, 731, 10.1042/bst0200731 Pastan, 1988, Selective killing of HIV-infected cells by a recombinant human CD4-Pseudomonas exotoxin hybrid protein., Nature (London), 335, 369, 10.1038/335369a0 Bastos, 1990, Concomitant administration of hapten and IL-2-toxin (DAB486-IL-2) results in specific deletion of antigen activated T cell clones, J. Immunol., 145, 3535, 10.4049/jimmunol.145.11.3535 Sasaki, 1984, Daunomycin-arachidonic acid complex as a potential new anti-tumor agennt, Cancer Chemother. Pharmacol., 13, 75, 10.1007/BF00257117 Akiyama, 1984, Verapamil enhances the toxicity of conjugates of epidermal growth factor with pesudomonas exotoxin and antitrasferrin receptor with pseudomonas exotoxin, J. Cell. Physiol., 120, 271, 10.1002/jcp.1041200303 Kohler, 1975, Continuous cultures of fused cells secreting antibody of predefined specificity., Nature (London), 256, 495, 10.1038/256495a0 Pietersz, 1992, Antibody conjugates for the treatment of cancer, Immunol. Rev., 129, 57, 10.1111/j.1600-065X.1992.tb01419.x P. Ehrlich., “Collected Studies in Immunity,” Vol. 11. Wiley, New York. Mathe, 1958, Effet sur la Ieucemie 1210 de la souris d'un combinaison par diazotation d'Amethopterine et de gamma globulines de hamsters porteurs de cette leucemie par hetirogreffe, C. R. Acad. Sci D Paris, 246, 1626 Ghose, 1972, Immunochemotherapy of cancer with chlorambucil-carrying antibody., Br. Med. J., 3, 495, 10.1136/bmj.3.5825.495 Arnon, 1979, 287 Ghose, 1978, Antibody linked cytotoxic agents in the treatment of cancer: Current status and future prospects, J. Natl. Cancer Inst., 61, 657 Hurwitz, 1975, The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities, Cancer Res., 35, 1175 Herberman, 1975, Problems associated with study of cell-mediated immunity to human tumours by microcytotoxicity assays, J. Natl. Cancer Inst., 55, 749, 10.1093/jnci/55.4.749 Schroff, 1985, Intratumor localization of monoclonal antibody in patients with melanoma treated with antibody to a 250,000 dalton melanoma associated antigen, J. Natl. Cancer Inst., 74, 299 Herlyn, 1980, Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody, Cancer Res., 40, 717 Katano, 1984, Human monoclonal antibody to tumor-associated ganglioside GD2: Suppressed growth of human melanoma in nude mice, Immunol. Lett., 8, 169, 10.1016/0165-2478(84)90072-5 Dillman, 1989, Murine monoclonal antibody therapy in two patients with chronic lymphocytic leukaemia, Blood, 59, 1036, 10.1182/blood.V59.5.1036.1036 Miller, 1981, Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody, Lancet, 2, 226, 10.1016/S0140-6736(81)90475-X Ritz, 1981, Serotherapy of acute lymphoblastic leukaemia with monoclonal antibody, Blood, 58, 141, 10.1182/blood.V58.1.141.141 Adams, 1984, Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis, Proc. Natl. Acad. Sci. U.S.A, 81, 3506, 10.1073/pnas.81.11.3506 Goodman, 1985, Pilot trial of murine monoclonal antibodies in patients with advanced melanoma, J. Clin. Oncol., 3, 340, 10.1200/JCO.1985.3.3.340 Sears, 1982, Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours, Lancet, 1, 762, 10.1016/S0140-6736(82)91811-6 Feinerman, 1983, Treatment of murine leukaemia with chlorambucil bound monoclonal antibodies, Adv. Exp. Med. Biol., 166, 59, 10.1007/978-1-4757-1410-4_6 Debure, 1988, One-month prophylactic use of OKT3 in cadaver kidney transplant recipients, Transplantation, 45, 546, 10.1097/00007890-198803000-00009 Dyer, 1990, Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies, Leukaemia Lymphoma, 2, 179, 10.3109/10428199009053522 Adair, 1992, Engineered antibodies for therapy, Immunol. Rev., 130, 5, 10.1111/j.1600-065X.1992.tb01519.x Michaelson, 1992, Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge regions, Mol. Immunol., 29, 319, 10.1016/0161-5890(92)90018-S Guadagni, 1988, Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon, Cancer Immunol. Immunother., 26, 222, 10.1007/BF00199933 Vuist, 1990, Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies, Cancer Res., 50, 5767 Bock, 1991, Biological and antitumor effects of recombinant human macrophage colony stimulating factor in mice., Cancer Res., 51, 2649 1985 Thielemans, 1984, Strategies for production of monoclonal anti-idiotype antibodies against human B cell lymphomas, J. Immunol., 133, 495, 10.4049/jimmunol.133.1.495 Abelev, 1963, Reduction of embryonal α-globulin by transplantable mouse hepatomas, Transplantation, 1, 174, 10.1097/00007890-196301020-00004 Gold, 1965, Demonstration of tumor-specific antigen in human colonic carcinomata by immunological tolerance and absorption technique, J. Exp. Med., 121, 439, 10.1084/jem.121.3.439 Greaves, 1975, Antisera to acute lymphoblastic leukaemia cells, Clin. Immunol. Immunopathol., 4, 67, 10.1016/0090-1229(75)90041-0 Corvalan, 1984, Classification of anti-CEA monoclonal antibodies, Protides Biol. Fluids, 31, 921, 10.1016/B978-0-08-030764-0.50209-3 Hedin, 1982, Specificities and binding properties of eight monoclonal antibodies against carcinoembryonic antigen, Mol Immunol., 19, 1641, 10.1016/0161-5890(82)90275-9 Micheel, 1983, Monoclonal antibodies to different epitopes on human α-fetoprotein (AFP), Eur J. Cancer Clin. Oncol., 19, 1239, 10.1016/0277-5379(83)90201-8 Rogers, 1983, Binding studies on two different monoclonal antibodies raised against CEA, Eur. J. Cancer Clin. Oncol., 19, 629, 10.1016/0277-5379(83)90179-7 von Kleist, 1972, Identification of a normal antigen that cross-reacts with the carcinoembryonic antigen, Proc. Natl. Acad. Sci. U.S.A., 69, 2492, 10.1073/pnas.69.9.2492 Burtin, 1973, Characterisation of a second normal antigen that cross reacts with CEA, J. Immunol., 111, 1926, 10.4049/jimmunol.111.6.1926 Svenberg, 1976, Carcinoembryonic antigen-like substances of human bile: Isolation and partial characterisation, Int. J. Cancer, 17, 588, 10.1002/ijc.2910170506 Dillman, 1984, Lack of radioimmunodetection and complications associated with monoclonal anti-carcinoembryonic antigen antibody crossreactivity with an antigen on circulating cells, Cancer Res., 44, 2213 Harwood, 1986, Mapping epitope characteristics on carcinoembryonic antigen, Br. J. Cancer, 54, 75, 10.1038/bjc.1986.154 Zimmerman, 1987, Isolation and characterization of cDNA clones encoding the human carcinoembryonic antigen reveal a highly conserved repeating structure, Proc. Natl. Acad. Sci. U.S.A., 84, 2960, 10.1073/pnas.84.9.2960 Hass, 1991, Preparation of synthetic polypeptide domains of carcinoembryonic antigen and their use epitope mapping, Cancer Res., 51, 1876 Neville, 1976, Biochemical monitoring of cancer, Ann. Clin. Biochem., 13, 283, 10.1177/000456327601300101 Begent, 1985, Recent advances in tumour imaging: Use of radiolabelled antitumour antibodies, Biochem. Biophys. Acta, 780, 151 A.G. Casson., C.H. J. Ford., and H. Marsden., M.E. Gallant., S.E. Bartlett., (1986) “Efficacy of Monoclonal Anti-CEA Antibody-Vindesine Conjugate on Five Human Tumour Cell Lines Grown as Xenografts in Nude Mice: NCL Monographs. Brown, 1981, Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies, J. Immunol., 127, 539, 10.4049/jimmunol.127.2.539 Cuttitta, 1981, Monoclonal antibodies that demonstrate specificity for several types of human lung cancer, Proc. Natl. Acad. Sci. U.S.A., 78, 4591, 10.1073/pnas.78.7.4591 Schlom, 1984, Monoclonal antibodies to breast cancer associated antigens as potential reagents in the management of breast cancer, Cancer, 54, 2777, 10.1002/1097-0142(19841201)54:2+<2777::AID-CNCR2820541426>3.0.CO;2-D Ball, 1982, Monoclonal antibodies reactive with human myeloid leukaemia cells, Clin. Exp. Immunol., 48, 655 Levy, 1979, A human thymus-leukaemia antigen defined by hybridoma monoclonal antibodies, Proc. Natl. Acad. Sci. U.S.A., 76, 6552, 10.1073/pnas.76.12.6552 Nadler, 1980, A monoclonal antibody defining a lymphoma associated antigen in man, J. Immunol., 125, 570, 10.4049/jimmunol.125.2.570 Feizi, 1985, Demonstration by monoclonal antibodies that carbohydrate structures of glycoproteins and glycolipids are onco-developmental antigens., Nature (London), 314, 53, 10.1038/314053a0 Harper, 1984, Characterization of monoclonal antibody 155.8 and partial characterization of its proteoglycan antigen on human melanoma cells, J. Immunol., 132, 2096, 10.4049/jimmunol.132.4.2096 Slamon, 1987, Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106 Embleton, 1983, Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate, Br. J. Cancer, 47, 43, 10.1038/bjc.1983.5 Heldin, 1984, Growth factors; Mechanism of action and relation to oncogenes., Cell (Cambridge, Mass.), 37, 9, 10.1016/0092-8674(84)90296-4 Chen, 1992, T-cell immunity to the joining region of p210BCR-ABL protein, Proc. Natl. Acad. Sci. U.S.A., 89, 1468, 10.1073/pnas.89.4.1468 Shipp, 1988, Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type of integral membrane protein, Proc. Natl. Acad. Sci. U.S.A., 85, 4819, 10.1073/pnas.85.13.4819 Gendler, 1988, A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats, J. Biol. Chem., 263, 12,820, 10.1016/S0021-9258(18)37632-4 Vikko, 1988, Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase, FEBS Lett, 236, 275, 10.1016/0014-5793(88)80037-1 Xing, 1992, Second generation monoclonal antibodies to intestinal MUC2 peptides reactive with colon cancer, J. Natl. Cancer Inst., 84, 699, 10.1093/jnci/84.9.699 Buchegger, 1983, Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice, J. Exp. Med., 158, 413, 10.1084/jem.158.2.413 Goldenberg, 1983, In vivo use of radioactive antibodies against prostatic acid phosphatase for diagnosis and detection of prostatic cancer by nuclear imaging, J. Am. Med Assoc., 250, 630, 10.1001/jama.1983.03340050042026 Rainsbury, 1983, Localisation of metastatic breast carconima by a monoclonal antibody chelate labelled with indium-lll., Lancet, ii, 934, 10.1016/S0140-6736(83)90452-X Larson, 1983, Localization of 131L-labelled p97 specific Fab fragments in human melanoma as a basis for radiotherapy, J. Clin. Invest., 72, 2101, 10.1172/JCI111175 Pimm, 1982, In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts, Int. J. Cancer, 30, 75, 10.1002/ijc.2910300114 Foon, 1983, Monoclonal antibody therapy: Assessment by animal tumor models, J. Biol Response Modif., 1, 277 Baldwin, 1983, Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting, Cancer Metast. Rev., 2, 89, 10.1007/BF00046907 Armitage, 1984, The localization of an anti-tumour monoclonal antibody (791T/36) in gastrointestinal tumours, Br. J. Surg., 71, 407, 10.1002/bjs.1800710602 Durrant, 1986, Association of antigen expression and DNA ploidy in colorectal tumors, Cancer Res., 46, 3543 Andrew, 1990, Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM 1899), Cancer Res, 50, 5225 Ceriani, 1987, Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components, Cancer Res., 47, 532 Smyth, 1993, Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin-monoclonal antibody conjugates, Immunol. Cell Biol., 71, 167, 10.1038/icb.1993.19 DeDuve, 1974, Lysomotropic agents, Biochem. Pharmacol., 23, 2495, 10.1016/0006-2952(74)90174-9 Uhr, 1984, Immunotoxins: Harnessing nature's poisons, J. Immunol., 133, i, 10.4049/jimmunol.133.6.i Aboud-Pirack, 1988, Binding and endocytosis of a monoclonal antibody to a high molecular weight human milk fat globule membrane—associated antigen by cultured MCF-7 breast cancer cells, Cancer Res., 48, 3188 Casellas, 1982, Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97, Int. J. Cancer, 30, 437, 10.1002/ijc.2910300410 Carriäre, 1985, Endocytosis of an antibody ricin A-chain conjugate (immuno-A-toxin) absorbed on colloidal gold, Exp. Cell Res., 156, 327 Della Torre, 1987, Internalization of a monoclonal antibody against human breast cancer by immunoelectron microscopy, Br. J. Cancer, 55, 357, 10.1038/bjc.1987.72 Jansen, 1982, Immunotoxins: Hybrid molecules containing high specificity and potent cytotoxicity, Immunol. Rev., 62, 185, 10.1111/j.1600-065X.1982.tb00394.x Kagen, 1981, Diptheria toxin fragment forms large pores in phospholipid bilayer membranes, Proc. Natl. Acad. Sci. U.S.A., 78, 4950, 10.1073/pnas.78.8.4950 Thorpe, 1984, Blockade of the galactose-binding sites of ricin by its linkage to antibody: Specific cytotoxic effects of the conjugates, Eur. J. Biochem., 140, 63, 10.1111/j.1432-1033.1984.tb08067.x Vitetta, 1983, Immunotoxins: A new approach to cancer therapy and immunoregulation, Science, 219, 644, 10.1126/science.6218613 Machy, 1982, Differential endocytosis of T and B lymphocyte surface molecules evaluated with antibody-bearing fluorescent liposomes containing methotrexate, Proc. Natl. Acad. Sci. U.S.A., 79, 4148, 10.1073/pnas.79.13.4148 Poste, 1983, The challenge of liposome targeting in vivo., 3, 1 Poste, 1983, Site-specific (targeted) drug delivery in cancer therapy, Biotechnology, 1, 869, 10.1038/nbt1283-869 Manske, 1986, Antigenic modulation by anti-CD5 immunotoxins, J. Immunol., 136, 4721, 10.4049/jimmunol.136.12.4721 Starling, 1991, In vivo antitumor activity of a monoclonal antibody vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibodyantigen complexes, Cancer Res., 51, 2965 Mach, 1980, Tumor localization of radiolabelled antibodies against carcino-embryonic antigen in patients with carcinoma: A critical evaluation, N. Engl. J. Med., 303, 5, 10.1056/NEJM198007033030102 Meeker, 1985, A clinical trial of anti-idiotype therapy for B cell malignancy, Blood, 65, 1349, 10.1182/blood.V65.6.1349.bloodjournal6561349 Senter, 1988, Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate, Proc. Natl. Acad. Sci. U.S.A., 85, 4842, 10.1073/pnas.85.13.4842 Kerr, 1991, Targeting 5-fluorouracil to tumors using antibody-cytosine deaminase conjugates in combination with 5-fluorocytosine. Abstract P97 in Proceedings of the Sixth International Conference on Monoclonal Antibody Immunoconjugates for cancer, Antibiot. Immunoconj. Radiopharm., 4, 229 Andrew, 1986, Comparative imaging and biodistribution studies with an anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts, Eur. J. Nucl. Med., 12, 168, 10.1007/BF00256915 Covell, 1986, Pharmacokinetics of nonoclonal immunoglobulin G1, F(ab')2, and Fab' in mice, Cancer Res., 46, 3969 Masuho, 1982, Importance of the antigen-binding valency and the nature of the crosslinking bond in ricin A-chain conjugates with antibody, Biochem. J., 9, 1583, 10.1093/oxfordjournals.jbchem.a133849 Parham, 1983, On the fragmentation of monoclonal IgG1, IgG2a and IgG2b from Balb/c mice, J. Immunol., 131, 2895, 10.4049/jimmunol.131.6.2895 Smyth, 1986, Selective enhancement of antitumour activity of N-acetyl melphalan on conjugation to monoclonal antibodies, Cancer Res., 47, 62 Smyth, 1987, The in vitro and in vivo anti-tumour activity of N-AcMEL-F(ab')2 conjugates, Br. J. Cancer, 55, 7, 10.1038/bjc.1987.2 Ghose, 1988, Synthesis and testing of antibody antifolate conjugates for drug targeting., 81 Ghetie, 1988, Large scale preparation of immuntoxins constructed with the Fab' fragment of IgG1 murine monoclonal antibodies and chemically deglycosylated ricin A chain, J. Immunol. Methods, 112, 267, 10.1016/0022-1759(88)90367-5 Better, 1988, Escherichia coli secretion of an active chimeric antibody fragments., Science, 240, 1041, 10.1126/science.3285471 Khazaeli, 1988, Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A: Pharmacokinetics and immune response, J. Natl. Cancer Inst., 80, 937, 10.1093/jnci/80.12.937 LoBuglio, 1989, Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response, Proc. Natl. Acad. Sci. U.S.A., 86, 4220, 10.1073/pnas.86.11.4220 Huston, 1988, Proteins engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc., Natl. Acad. Sci. U.S.A., 85, 5879, 10.1073/pnas.85.16.5879 Glockshuber, 1990, A comparison of strategies to stabilize immunoglobulin Fv fragments, Biochemistry., 29, 1362, 10.1021/bi00458a002 Yokota, 1992, Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms, Cancer Res., 52, 3402 Colcher, 1990, In vivo tumor targeting of a recombinant single-chain antigen binding protein, J. Natl. Cancer. Inst., 82, 1191, 10.1093/jnci/82.14.1191 Primus, 1980, Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen, Cancer Res., 40, 497 Carrasquillo, 1984, Diagnosis of and therapy for solid tumours with radio-labeled antibodies and immune fragments, Cancer Treat. Rep., 68, 317 Courtenay-Luck, 1986, Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms, Cancer Res., 46, 6489 Levy, 1983, Tumor therapy with monoclonal antibodies, Fed. Proc., 42, 2650 Tjandra, 1989, Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma—A preliminary report, Surgery, 106, 533 Kitamura, 1991, Chemical engineering of the monoclonal antibody A7 by polyethelene glycol for targeting cancer therapy, Cancer Res., 51, 4310 Lowder, 1987, Suppression of anti-mouse immunoglobulin antibodies in subhuman primates receiving murine-monoclonal antibodies against T cell antigens, J. Immunol., 138, 401, 10.4049/jimmunol.138.2.401 McDonald, 1986, Genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, J. Immunol., 137, 1066, 10.4049/jimmunol.137.3.1066 Kameyama, 1989, Convenient plasmid vectors for construction of chimeric mouse/human antibodies, FEBS Lett., 244, 301, 10.1016/0014-5793(89)80550-2 Beidler, 1988, Cloning and high level expression of a chimeric antibody with specificity for human carcioembryonic antigen, J. Immunol., 141, 4053, 10.4049/jimmunol.141.11.4053 Hale, 1988, Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H, Lancet, 17, 1394, 10.1016/S0140-6736(88)90588-0 Sikora, 1983, Human hybridomas from patients with malignant disease, Br. J. Cancer, 47, 135, 10.1038/bjc.1983.16 Kozbor, 1984, A human hybrid myeloma for production of human monoclonal antibodies, J. Immunol., 133, 3001, 10.4049/jimmunol.133.6.3001 Irie, 1986, Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2, Proc. Natl. Acad. Sci. U.S.A., 83, 8694, 10.1073/pnas.83.22.8694 McCabe, 1988, Preclinical studies on the pharmacokinetic properties of human monoclonal antibodies to colorectal cancer and their use for detection of tumors., Cancer Res., 4348 Gallego, 1984, Preparation of four daunomycin monoclonal antibody 791T/36 conjugates with anti-tumor activity, Int. J. Cancer, 33, 737, 10.1002/ijc.2910330605 Pietersz, 1987, The use of anthracycline antibody complexes for specific anti-tumor therapy., 1 1980, 16 Shen, 1986, Targeting internalization and cytotoxicity of methotrexate-monoclonal anti-stage specific embryonic antigen-1 antibody conjugates in cultured F.9 teratocarcinoma cells, Cancer Res., 46, 3912 Hurwitz, 1985, The covalent linking of two nucleotide analogues to antibodies, J. Med. Chem., 28, 137, 10.1021/jm00379a023 Kanellos, 1987, Antitumor activity of aminopterin-monoclonal antibody conjugates: In vitro and in vivo comparison with methotrexate monoclonal antibody conjugates, Immunol. Cell. Biol., 65, 483, 10.1038/icb.1987.57 Goerlach, 1991, In vitro antitumor activity of 2′-deoxy-5-fluorouridine monoclonal antibody conjugates., Bioconj. Chem., 2, 96, 10.1021/bc00008a004 Smyth, 1986, The specific targeting of chlorambucil to tumours, J. Natl. Cancer Inst., 76, 503 Li, 1990, Preparation of antigastric cancer monoclonal antibody MGb2-mitomycin C conjugate with improved antitumor activity, Bioconj. Chem., 1, 245, 10.1021/bc00004a003 Koch, 1991, In vitro activity of immunoconjugates between cis-platinum and monoclonal antibodies, Antibiot. Immunoconj. Radiopharm., 2, 121 Linford, 1974, An alkylating agent-globulin conjugate with both alkylating and antibody activity, J. Natl. Cancer Inst., 52, 1665, 10.1093/jnci/52.5.1665 Rowland, 1975, Suppression of tumor growth in mice by a drug-antibody conjugate using a novel approach to linkage., Nature (London), 255, 487, 10.1038/255487a0 Sivam, 1990, Immunoconjugates of a small molecule protein synthesis inhibitor (trichothecene)—an update. Abstract 102, in Proceeding of the 5th International Conference on Monoclonal Antibody Conjugates for Cancer, Antib. Immunoconj. Radiopharma., 3, 63 Ohtani, 1990, Antitumor activity of T-2 toxin-conjugated monoclonal antibody to murine thymoma, Jpn. J. Exp. Med., 60, 57 Laguzza, 1989, New antitumor monoclonal antibody-vinca conjugates LY-203725 and related compounds: Design, preparation, and representative in vivo activity, J. Med. Chem., 32, 548, 10.1021/jm00123a007 Cotter, 1984, Monoclonal antibody mediated delivery of deacetylcolchicine to human peripheral blood neutrophils, Biochem. Soc. Trans., 12, 452, 10.1042/bst0120452 Pietersz, 1991, Conjugation in vitro and in vivo efficacy of highly cytotoxic anticancer drugs—Aminopterin (AMN), 5-fluoro-2-deoxyuridine (5-FUDr) and podophyllotoxin. Abstract P-85., 4, 226 Sweet, 1989, Daunorubicin conjugated to a monoclonal anti-CA125 antibody selectively kills human ovarian cancer cells, Gynecol. Oncol., 34, 305, 10.1016/0090-8258(89)90163-7 Galun, 1990, The effect of anti-α-fetoprotein adriamycin conjugate on a human hepatoma, Hepatology, 11, 578, 10.1002/hep.1840110409 Manabe, 1983, Production of a monoclonal antibody-bleomycin conjugate utilising dextran T-40 and the antigen-targeting cytotoxicity of the conjugates, Biochem. Biophys. Res. Commun., 115, 1009, 10.1016/S0006-291X(83)80035-7 Pietersz, 1988, Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates, Cancer Res., 48, 926 Manabe, 1984, Production of a macromomycin (MRC)—monoclonal antibody conjugate and its biological activity, Biochem. Pharmacol., 33, 2143, 10.1016/0006-2952(84)90585-9 Mueller, 1991, Preclinical therapy of human melanoma with morpholino-doxorubicin conjugated to a monoclonal antibody directed against an integrin on melanoma cells, Antibiot. Immunoconj. Radiopharm., 2, 99 Hermentin, 1991, Attachment of rhodosaminylanthracyclinone-type anthracyclines to the hinge region of monoclonal antibodies, Bioconj. Chem., 2, 100 Greenfield, 1991, 13-Acylhydrazone anthracycline immunoconjugates: Improved therapy by linking carminomycin a more potent analog of adriamycin to the anticarcinoma MAB BR64. Abstract P.89., 4, 227 Iwahashi, 1989, Selective killing of carcinoembryonic-antigen (CEA) producing cells in vitro by the immunconjugate cytorhodin-S and CEA-reactive cytorhodin-S antibody CA208, Cancer Immunol. Immunother., 30, 239, 10.1007/BF01665011 Alberici, 1988, Conjugates of elliptinium acetate with mouse monoclonal anti-α-fetoprotein antibodies or Fab fragments: In vitro cytotoxic effects upon human hepatoma cell lines, Int. J. Cancer, 41, 309, 10.1002/ijc.2910410224 Chari, 1990, Abstract 104 in Proceedings of the 5th International Conference on Monoclonal Antibody Immunoconjugates for Cancer, Antibiot. Immunoconj. Radiopharm, 3, 64 Hinman, 1990, Abstract 84 in Proceedings of the 5th International Conference on Monoclonal Antibody Immunoconjugates for Cancer, Antibiot. Immunoconj. Radiopharm., 3, 59 Rodwell, 1986, Site specific covalent modification of monoclonal antibodies: In vitro and in vivo evaluations, Proc. Natl. Acad. Sci. U.S.A., 83, 2632, 10.1073/pnas.83.8.2632 Endo, 1987, A novel covalent modification of antibodies at their amino groups with retention of antigen binding activity, J. Immunol. Methods, 104, 253, 10.1016/0022-1759(87)90512-6 Avrameas, 1969, Coupling of enzymes to proteins with glutaraldehyde: Use of conjugates for the detection of antigens and antibodies, Immunochemistry, 6, 43, 10.1016/0019-2791(69)90177-3 Mohamed, 1986, Analysis of adriamycin linked to an anti-sarcoma monoclonal antibody, Pro. A.A.C.R., 27, 317 Hurwitz, 1985, The covalent linking of two nucleotide analogues to antibodies, J. Med. Chem., 28, 137, 10.1021/jm00379a023 Carraway, 1972, Carbodiimide modification of proteins, Methods Enzymol., 25, 616, 10.1016/S0076-6879(72)25060-1 Timkovich, 1977, Polymerization side reactions during protein modification with carbodiimide, Biochem. Biophys. Res. Commun., 74, 1463, 10.1016/0006-291X(77)90606-4 Kulkarni, 1981, Covalent binding of methotrexate to immunoglobulins and the effect of antibody-linked drug on tumor growth in vivo, Cancer Res., 41, 2700 Anderson, 1964, The use of esters of N-hydroxysuccinimide in peptide synthesis, J. Am. Chem. Soc., 86, 1839, 10.1021/ja01063a037 Martin, 1971, Enhanced immunogenicity of chemically coated syngeneic tumor cells, Proc. Natl. Acad. Sci. U.S.A., 68, 469, 10.1073/pnas.68.2.469 Endo, 1988, Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: Implications for future preparation of conjugates, Cancer Res., 48, 3330 Yang, 1988, Doxorubicin conjugated with a monoclonal antibody directed to a melanoma associated proteoglycan suppresses the growth of established tumour xenografts in nude mice, Proc. Natl. Acad. Sci. U.S.A., 85, 1189, 10.1073/pnas.85.4.1189 Dillman, 1988, Superiority of an acid-labile daunorubicin-monoclonal antibody immunoconjugate compared to free drug, Cancer Res., 48, 6097 Burnstein, 1977, Chemotherapy of murine ovarian carcinoma by methotrexate-antibody conjugates, J. Med. Chem., 20, 950, 10.1021/jm00217a018 Latif, 1980, Evaluation of drug-antibody conjugates in the treatment of human myelosarcomas transplanted in nude mice, Cancer (Philadelphia), 45, 1326, 10.1002/1097-0142(19800315)45:6<1326::AID-CNCR2820450610>3.0.CO;2-Y De Carvalho, 1964, Coupling of cyclic chemotherapeutic compounds to immune γ globulins., Nature (London), 202, 255, 10.1038/202255a0 Calendi, 1969, Histoimmunologic specificity of an anti-lymphoid tissue sarcoma γ-globulin bound to methotrexate, Bull. Chim. Farm., 108, 25 Robinson, 1973, Cell directed antimetabolites: Alternative syntheses of cytotoxic methotrexate-containing macromolecules, Biochem. Soc. Trans., 1, 722, 10.1042/bst0010722 Harding, 1971, Amethopterin linked covalently to water soluble macromolecules, Ann. N. Y. Acad. Sci., 186, 270, 10.1111/j.1749-6632.1971.tb46981.x Worrell, 1986, Effect of linkage variation on pharmacokinetics of ricin. A chain-antibody conjugates in normal rats, Anti Cancer Drug Design., 1, 179 Letvin, 1986, In vivo administration of lymphocyte-specific monoclonal antibodies in non human primates: In vivo stability of disulfide-linked immunotoxin conjugates, J. Clin. Invest., 77, 977, 10.1172/JCI112399 Cumber, 1985, 112, 207 Carlsson, 1978, Protein thiolation and reversible protein-protein conjugation: N-succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent, Biochem J., 173, 723, 10.1042/bj1730723 Miyazaki, 1980, Preparation of antibody (IgG)-ricin A-chain conjugate and its biologic activity, Gann, 71, 766 Weil-Hillman, 1985, Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model, Cancer Res., 45, 1328 Thorpe, 1987, New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo, Cancer Res., 47, 5924 Garnett, 1983, Preparation and properties of a drug-carrier-antibody conjugate showing selective antibody-directed cytotoxicity in vitro, Int. J. Cancer, 31, 661, 10.1002/ijc.2910310520 Abuchowski, 1977, Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol, J. Biol. Chem., 252, 3578, 10.1016/S0021-9258(17)40291-2 Guclu, 1976, Binding of chlorambucil with antitumor globulines and its effect on drug and antibody activities, Eur. J. Cancer, 12, 95, 10.1016/0014-2964(76)90211-5 Apelgren, 1990, Antitumor activity of the monoclonal antibody vinca alkaloid immunconjugate LY203725 (KS 1/4-4-desacetylvinblastine-3-carboxyhydrazide) in a nude mouse model of human ovarian cancer, Cancer Res., 50, 3540 Bumol, 1988, KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies., 55 Goldmacher, 1992, Photoactivation of toxin conjugates, Bioconj. Chem., 3, 104, 10.1021/bc00014a003 Pietersz, 1988, Specific in vitro antitumour activity of methotrexate-monoclonal antibody conjugates prepared using human serum albumin as an intermediary, Immunol. Cell. Biol., 66, 43, 10.1038/icb.1988.5 Kanellos, 1985, Studies of methotrexate-monoclonal antibody conjugates for immunotherapy, J. Natl. Cancer. Inst., 75, 319 Hurwitz, 1980, Soluble macromolecules as carriers for daunorubicin, J. Appl. Biochem., 2, 25 Shih, 1990, A fluorouridine-anti-CEA immunoconjugate is therapeutically effective in a human colonic cancer xenograft model, Int. J. Cancer, 46, 1101, 10.1002/ijc.2910460625 Tsukada, 1985, Suppression of human α-fetoprotein-producing hepatocellular carcinoma growth in nude mice by an anti α-fetoprotein antibody-daunorubicin conjugate with a poly-L-glutamic acid derivative as intermediate drug carrier, Br. J. Cancer, 52, 111, 10.1038/bjc.1985.157 Ohkawa, 1986, Selective in vitro and in vivo growth inhibition against human yolk sac tumor cell lines by purified antibody against human α-fetoprotein conjugated with mitomycin C via human serum albumin, Cancer Immunol. Immunother, 23, 81, 10.1007/BF00199811 Hakala, 1974, Transport of antineoplastic agents, Handb. Exp. Pharmakol., 34, 240 Shen, 1981, Cis-aconityl spacer between daunomycin and macromolecular carriers: A model of pH-sensitive linkage releasing drug from a lysosomotropic conjugate, Biochem. Biophys. Res. Commun., 102, 1049, 10.1016/0006-291X(81)91644-2 Peterson, 1978, Transport and storage of daunorubicin and doxorubicin in cultured fibroblasts, Cancer Res., 38, 4645 Rowland, 1985, Antitumor properties of vindesine-monoclonal antibody conjugates, Cancer Immunol. Immunother., 19, 1, 10.1007/BF00199304 Bradford, 1976, A rapid and sensitive method of quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Anal. Biochem., 72, 248, 10.1016/0003-2697(76)90527-3 Garnett, 1985, Studies on the mechanism of action of an antibody targeted drug-carrier conjugate, Anti Cancer Drug Design, 1, 3 Ichihashi, 1984, Application of radioactive precursors for the evaluation of sensitivity of cancer cells to anticancer drugs, Oncology, 41, 88, 10.1159/000225799 Mew, 1985, Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin in label and kill selected cell lines subsequent to light activation, Cancer Res., 45, 4380 Ford, 1989, Comparison of tetrazolium colorimetric and 3H-uridine assays for in vitro chemosensitivity testing, Cancer Chemother. Pharmacol., 24, 295, 10.1007/BF00304761 Epstein, 1955, Use of α-(4-nitrobenzyl)pyridine as analytical reagent for ethylenimines and alkylating agents, Anal. Chem., 27, 1435, 10.1021/ac60105a022 Parish, 1978, A sensitive rosetting method for detecting subpopulations of lymphocytes which react with alloantisera, J. Immunol. Methods, 20, 173, 10.1016/0022-1759(78)90254-5 Robbins, 1986, Measurement of tumour reactive antibody and antibody conjugate by competition quantitated by flow cytofluorometry, J. Immunol. Methods, 90, 165, 10.1016/0022-1759(86)90072-4 Tsukada, 1982, Effect of a conjugate of daunomycin and antibodies to rat α-fetoprotein on the growth of α-fetoprotein-producing tumor cells, Proc. Natl. Acad. Sci. U.S.A., 79, 621, 10.1073/pnas.79.2.621 Blakey, 1987, Antitumor activity of a panel of anti-Thy1.2 immunotoxins made with different ribosome-inactivating proteins., 195 Pietersz, 1987, The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer, Immunol. Cell. Biol., 65, 111, 10.1038/icb.1987.13 Kishida, 1983, Ricin A-chain conjugated with anti-L1210 antibody: In vitro and in vivo antitumor activity, Cancer Immunol. Immunother., 16, 93, 10.1007/BF00199238 Krollick, 1982, In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins., J. Exp. Med., 155, 1797, 10.1084/jem.155.6.1797 Shah, 1993, Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumour models, Cancer Res., 53, 1360 Philips, 1989, Growth of human tumors in immunodeficient SCID mice and nude mice Cancer Top., Microbiol. Immunol., 152, 259 Ghetie, 1992, The antitumor activity of an anti-CD22 immunotoxin in SCID mice with disseminated daudi lymphoma in enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin, Blood, 80, 2315, 10.1182/blood.V80.9.2315.2315 Smyth, 1991, The antitumor activity of idarubicin monoclonal antibody conjugates in a disseminated thymoma model, Cancer Res., 51, 310 K. Krauer., (1992) “Drug Immunoconjugates in the Treatment of Cancer.” University of Melbourne. Maier, 1991, Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2, Cancer Res., 51, 5361 Robbins, 1991, Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line, Cancer Res., 51, 3657 Hendrix, 1991, Radiolocalization and imaging stably PLAP-transfected MO4 tumors with monoclonal antibodies and fragments, Br. J. Cancer, 64, 1060, 10.1038/bjc.1991.465 Bresalier, 1987, An animal model for colon cancer metastasis: Establishment and characterization of murine cell lines with enhanced liver-metastasizing ability, Cancer Res., 47, 1398 Martin, 1986, Role of murine tumor models in cancer treatment research, Cancer Res., 46, 2189 Cline, 1975, Classes of chemotherapeutic agents., 35 Moore, 1968, Effects of chlorambucil (NSC-3088) in 374 patients with advanced cancer, Cancer Chemother. Rep., 52, 661 Hurwitz, 1982, Platinium-complexed antitumor immunoglobulins that specifically inhibit DNA synthesis of mouse tumor cells, J. Natl. Cancer Inst., 69, 47 O'Neill, 1975, In vitro cytotoxicity of anti-θ (Thy-1) antibodies combined with chlorambucil, Immunology., 28, 323 Blakeslee, 1975, Aggregation of chlorambucil in vitro may cause misinterpretation of protein binding data, Br. J. Cancer., 31, 689, 10.1038/bjc.1975.117 Tung, 1983, Cytotoxic effect of anti-idiotype antibody-chlorambucil conjugates against human lymphoblastoid cells, Immunology, 50, 57 Ross, 1975, The conjugation of chlorambucil with human γ-globulin, Chem. Biol. Interactions, 10, 169, 10.1016/0009-2797(75)90110-6 Rowland, 1977, Effective antitumour conjugates of alkylating drug and antibody using dextran as the intermediate carrier, Eur. J. Cancer, 13, 593, 10.1016/0014-2964(77)90121-9 Bernier, 1984, A chlorambucil-anti-CEA conjugate cytotoxic for human colon adenocarcinoma cells in vitro, Br. J. Cancer., 49, 245, 10.1038/bjc.1984.38 1977, 614 Rowland, 1975, Suppression of tumour growth in mice by a drug-antibody conjugate using a novel approach to linkage., Nature (London), 255, 487, 10.1038/255487a0 Linford, 1984, An alkylating agent-globulin conjugate with both alkylating and antibody activity, J. Natl. Cancer Inst., 52, 1665, 10.1093/jnci/52.5.1665 Warzynski, 1980, Conjugation of triaziquinone to immunoglobulin G by a thiolation procedure catalyzed by 2-pyridinealdoxime methiodide, J. Immunol. Methods, 35, 157, 10.1016/0022-1759(80)90160-X White, 1972, 25, 541 Davidson, 1975, “Platinum-pyrimidine blues” and related complexes: A new class of potent antitumor agents, Cancer Chemother. Rep., 59, 287 Suzuki, 1981, The preparation of mitomycin C, adriamycin and daunomycin covalently bound to antibodies as improved cancer chemotherapeutic agents, Chem. Pharm. Bull., 29, 844, 10.1248/cpb.29.844 Umemoto, 1984, Conjugates of mitomycin C with the immunoglobulin M fragment of a monoclonal anti-MM46 immunoglobulin M antibody with or without serum albumin as intermediary, J. Appl. Biochem., 6, 297 Manabe, 1985, Production of a monoclonal antibody mitomycin C conjugate, utilizing dextran-T40, and its biological activity, Biochem. Pharmacol., 34, 289, 10.1016/0006-2952(85)90140-6 Pietersz, 1990, Biodistribution of N-acetylmelphalan-monoclonal antibody conjugates in mice, Antibiot. Immunoconj. Radiopharm., 3, 27 Phillips, 1975, Some observations on the toxicity of adriamycin (NSC-123127), Cancer Chemother. Rep., 6, 177 Halazun, 1974, Daunorubicin cardiac toxicity in children with acute lymphoblastic leukemia, Cancer, 33, 545, 10.1002/1097-0142(197402)33:2<545::AID-CNCR2820330233>3.0.CO;2-M Lenaz, 1976, Cardiotoxicity of adriamycin and related anthracyclines, Cancer Treat. Rev., 3, 111, 10.1016/S0305-7372(76)80018-7 Levy, 1975, The specific cytotoxic effects of daunomycin conjugated to antitumor antibodies, Cancer Res., 35, 1182 Hurwitz, 1976, Fab dimers of antitumor immunoglobulins as covalent carriers of daunomycin, Cancer Biochem. Biophys., 1, 197 Hurwitz, 1978, Daunomycin-immunoglobulin conjugates, uptake and activity in vitro, Eur. J. Cancer, 14, 1213, 10.1016/0014-2964(78)90227-X Belles-Isles, 1980, In vitro activity of daunomycin-anti-α foetoprotein conjugate on mouse hepatoma cells, Br. J. Cancer, 41, 841, 10.1038/bjc.1980.153 Lee, 1978, The use of antifibrin antibodies for the destruction of tumor cells. III. Complete regression of MC-D sarcoma in guinea-pigs by conjugates of daunomycin with antifibrin antibodies, Cancer Immunol. Immunother., 5, 201, 10.1007/BF00199629 Richardson, 1989, Doxorubicin anti-carcinoembryonic antigen immunoconjugate activity in vitro., Eur. J. Clin. Oncol., 25, 633, 10.1016/0277-5379(89)90197-1 Shen, 1981, Conjugation of methotrexate to 5 basic polypeptides: Comparison of inhibitory effect on cells defective in drug transport, Fed. Proc., 40, 642 Diener, 1986, Specific immunosuppression by immunotoxins containing daunomycin, Science, 231, 148, 10.1126/science.3484557 Monsigny, 1980, Preparation and biological properties of a covalent antitumor drug-arm-carrier (DAC conjugate), FEBS Lett., 119, 181, 10.1016/0014-5793(80)81026-X Zunino, 1981, Biologic activity of daunorubicin linked to proteins via the methylketone side chain, Tumori, 67, 521, 10.1177/030089168106700602 Braslawsky, 1990, Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing, Cancer Res., 50, 6608 R.S. Greenfield., T. Kaneko., and A. Daues., M.A. Edson., K.A. Fitzgerald., L.J. Olech., J.A. Gratten., G.L. Spitalny., G.R. Braslawsky., Cancer Res. 50: 6600-6607. Kaneko, 1991, New hydrazone derivatives of adriamycin and their immunoconjugates a correlation between acid stability and cytotoxicity, Bioconj. Chem., 2, 133, 10.1021/bc00009a001 Hurwitz, 1978, The effect in vivo of chemotherapeutic drug-antibody conjugates in two murine experimental tumor systems, Int. J. Cancer, 21, 747, 10.1002/ijc.2910210612 Y. Tsukada., E. Hurwitz., and R. Kashi., M. Sela., N. Hibi., A. Hara., H. Hirai., Chemotherapy by intravenous administration of conjugates of daunomycin with monoclonal and conventional anti-rat α-fetoprotein antibodies. Proc. Natl. Acad. Sci. U.S.A. 79: 7896-7899. Ohkawa, 1986, Evaluation of a conjugate of purified antibodies against human AFP-dextran-daunorubicin to human AFP-producing yolk sac tumor cell lines, Cancer Immunol. Immunother., 22, 81, 10.1007/BF00199119 Tsukada, 1987, Therapeutic effect of treatment with polyclonal or monoclonal antibodies to α-fetoprotein that have been conjugated to daunomycin via a dextran bridge: Studies with an α-fetoprotein-producing rat hepatoma tumor model, Cancer Res., 47, 4293 Hurwitz, 1983, A conjugate of adriamycin and monoclonal antibodies to Thy-1 antigen inhibits human neuroblastoma cells in vitro, Ann. N.Y. Acad. Sci., 417, 125, 10.1111/j.1749-6632.1983.tb32857.x Tsukada, 1984, An anti-α-fetoprotein antibody-daunorubicin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier, J. Natl. Cancer Inst., 75, 721 Johns, 1973, Folate antagonists., 739 Whiteley, 1971, Some aspects of the chemistry of the folate molecule, Ann. N.Y. Acad. Sci., 186, 29, 10.1111/j.1749-6632.1971.tb46953.x Shen, 1986, Targeting: Internalisation and cytotoxicity of methotrexate-monoclonal anti-stage-specific embryonic antigen-1 antibody conjugates in cultured F-9 teratocarcinoma cells, Cancer Res., 46, 3912 Deguchi, 1986, Effect of methotrexate-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor, Cancer Res., 46, 3571 Garnett, 1986, An improved synthesis of a methotrexate-albumin-791T/36 monoclonal antibody conjugate cytotoxic to human osteogenic sarcoma cell lines, Cancer Res., 46, 2407 Pietersz, 1988, Specific in vitro anti-tumour activity of methotrexate-monoclonal antibody conjugates prepared using human serum albumin as an intermediary, Immunol. Cell Biol., 66, 43, 10.1038/icb.1988.5 Krauer, 1993, Aminopterin-monoclonal antibody conjugates: Antitumor activity and toxicity, Drug Targeting Delivery, 1, 27, 10.3109/10717549309031338 Johnson, 1980, In vitro cytotoxicity of anti-CEA immunoglobulin with cultured lung tumour cells, Br. J. Cancer, 42, 17 Johnson, 1981, A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro, Br. J. Cancer., 44, 472, 10.1038/bjc.1981.209 Conrad, 1979, Structure activity relationships of dimeric catharanthus alkaloid. 2. Experimental anti-tumour activities of N-substituted desacetyl vinblastine amide (vindesine) sulphates, J. Med. Chem., 22, 391, 10.1021/jm00190a008 Rowland, 1983, Monoclonal antibodies for targeted therapy with vindesine, Protides Biol. Fluids, 30, 375, 10.1016/B978-0-08-029815-3.50086-6 Rowland, 1984, Suppression of growth of a human colorectal tumour in nude mice by vindesine-monoclonal antibody conjugates, Protides Biol. Fluids, 31, 783, 10.1016/B978-0-08-030764-0.50177-4 Rowland, 1986, Drug localisation and growth inhibition studies of vindesine-monoclonal anti-CEA conjugates in a human tumour xenograft, Cancer Immunol. Immunother., 21, 183, 10.1007/BF00199359 Corvalan, 1987, Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids, Cancer Immunol. Immunother., 24, 127, 10.1007/BF00205589 Corvalan, 1987, Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids, Cancer Immunol. Immunother., 24, 133, 10.1007/BF00205590 Corvalan, 1987, Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody, Cancer Immunol. Immunother., 24, 138, 10.1007/BF00205591 Krauer, 1992, The anti-tumor effect of 2′-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts, Cancer Res., 52, 132 Hinman, 1993, Lysine-linked conjugates of N-acetyl calicheamycin γ1 with a fully humanized anti-polymorphic epithelial mucin antibody show potent antitumor effects in ovarian tumor xenografts., Proc. AACR. A.J. Rowland., I.F. C. McKenzie., and G.A. Pietersz., (1993) Preclinical investigation of the antitumour effects of anti-CD-19-idarubicin immunoconjugates. Cancer Immunol. Immunother., in press. Pietersz, 1989, Preclinical and clinical studies with N-acetyl melphalan immunoconjugates and tumour necrosis factor, Antibiot. Immunoconj. Radiopharm., 2, 47 Tai, 1976, Immunochemotherapy of mouse lymphoma with drug-antibody conjugate., Proc. Can. Fed. Biol. Sci., 19 Steinman, 1983, Endocytosis and the recycling of plasma membrane, J. Cell. Biol., 96, 1, 10.1083/jcb.96.1.1 Pastan, 1983, Receptor-mediated endocytosis: Coated pits, receptosomes and the golgi, Trends Biochem. Sci., 8, 250, 10.1016/0968-0004(83)90351-1 Rubens, 1974, Augmentation of cytotoxic drug action by antibodies directed at cell surface., Nature (London), 248, 81, 10.1038/248081a0 Davies, 1974, The combined effect of drugs and tumor specific antibodies in protection against a mouse lymphoma, Cancer Res., 34, 3040 Guclu, 1975, Endocytosis of chlorambucil-bound anti-tumour globulin following “capping” in EL4 lymphoma cells, Immunol. Commun., 4, 229, 10.3109/08820137409055776 Smyth, 1986, Potentiation of in vitro cytotoxicity of chlorambucil with monoclonal antibodies, J. Immunol., 37, 3361 Tritton, 1983, The anticancer agent adriamycin can be actively cytotoxic without entering cells, Science, 217, 248, 10.1126/science.7089561 Shen, 1982, The transport and release of poly (basic amino acids)-bound drugs in mammalian cells., 368 Shen, 1985, Disulfide spacer between methotrexate and poly(d-lysine), J. Biol. Chem., 260, 10,908, 10.1016/S0021-9258(17)39118-4 Uadia, 1985, Uptake of methotrexate linked to polyclonal and monoclonal anti-melanoma antibodies by a human melanoma cell line, J. Natl. Cancer Inst., 74, 29 Schneider, 1984, Lysosomal transport of cystine and other small molecules, Biochem. Soc. Trans., 12, 908, 10.1042/bst0120908 Silverstein, 1977, Endocytosis, Annu. Rev. Biochem., 46, 669, 10.1146/annurev.bi.46.070177.003321 Stahl, 1982, Expression of mannosyl fucosyl receptor function for endocytosis in cultured primary macrophages and their hybrids, J. Cell Biol., 93, 49, 10.1083/jcb.93.1.49 1984, Antibody-guided irradiation of malignant lesions: Three cases illustrating a new method of treatment., Lancet, 1, 1441 Epenetos, 1985, Antibody guided irradiation of brain glioma by arterial infusion of radioactive monoclonal antibody against epidermal growth factor receptor and blood group A antigen, Br. Med. J., 290, 1463, 10.1136/bmj.290.6480.1463 West, 1983, Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic chemotherapy for malignant gliomas: A follow up study, Neurosurgery, 13, 420, 10.1227/00006123-198310000-00013 Lee, 1987, Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration, Cancer Res., 47, 1941 D. Colcher., J.A. Carrasquillo., and J. Esteban., P. Sugarbaker., J.C.Reynolds., G. Bryant., S.M. Larson., J. Schlom., (1987) Complimentarity of intraperitoneal and intravenous administration of MoAb B72.3. “Second International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego.” H.J. Haisma., A. Battaile., K. Moseley., V.R. Zurawski. Jr., R.C. Knapp., (1987) Favourable tumor uptake of I-131 labelled monoclonal antibody OC125 after intraperitoneal administration as opposed to intravenous administration in ovarian cancer patients. In “Second International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego.” Weinstein, 1982, Monoclonal antibodies in the lymphatics: Toward the diagnosis and therapy of tumor metastases, Science, 218, 1334, 10.1126/science.7146917 Kitamura, 1992, Local administration of monoclonal antibody-drug conjugate: A new strategy to reduce the local recurrence of colorectal cancer, Cancer Res., 52, 6323 Weil-Hillman, 1987, Combined immunochemotherapy of human solid tumors in nude mice, Cancer Res., 47, 579 Kanellos, 1989, Intratumour therapy of solid tumours with the use of ricin-antibody conjugates, Immunol. Cell Biol., 647, 89, 10.1038/icb.1989.13 Pietersz, 1986, The use of whole ricin-antibody conjugates for the treatment of tumors in mice., 213 Pietersz, 1988, Novel synthesis and in vitro characterization of a disulfide linked ricin-monoclonal antibody conjugates devoid of galactose binding activity, Cancer Res., 48, 4469 1979 Sutherland, 1986, Importance of critical metabolites and cellular interactions in the biology of microregions of tumors, Cancer, 58, 1668, 10.1002/1097-0142(19861015)58:8<1668::AID-CNCR2820580816>3.0.CO;2-0 Teicher, 1981, Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoic tumor cells, Cancer Res., 41, 73 Guichard, 1980, Experimental data on the radiobiology of solid tumors, J. Eur. Radiother., 1, 171 Chaplin, 1987, Intermittent blood flow in a murine tumor: Radiobiological effects, Cancer Res., 47, 597 Duewell, 1986, Uptake of a monoclonal antibody against CEA (Tumak 431/31) in a human colon tumor (Co-112) xenografted in the nude mouse, Cancer Immunol. Immunother., 23, 101, 10.1007/BF00199814 Babbs, 1981, Physical principles of local heart therapy for cancer, Med. Instrum., 15, 367 Kahn, 1985, Epinephrine effect in selective renal angiography, Radiology, 85, 301, 10.1148/85.2.301 Hafstrom, 1980, Effects of catecholamines on cardiovascular response and blood flow distribution to normal tissue and liver tumors in rats, Cancer Res., 40, 481 Zanelli, 1975, The effect of anaesthetics on blood perfusion in transplanted tumours, Br. J. Cancer., 32, 380, 10.1038/bjc.1975.238 Smyth, 1987, The use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates, J. Natl. Cancer Inst., 79, 1367 Grega, 1986, Contractile elements in endothelial cells as potential targets for drug action, Trends Pharmacol. Sci., 7, 452, 10.1016/0165-6147(86)90419-0 MacPherson, 1986, Endotoxin-mediated necrosis and regression of established tumors in the mouse: A correlative study of quantitative changes in blood flow and ultrastructural morphology, Cancer Immunol. Immunother., 21, 209, 10.1007/BF00199364 Regenass, 1987, Anti-tumor effects of tumor necrosis factor in combination with chemotherapeutic agents, Int. J. Cancer, 39, 266, 10.1002/ijc.2910390224 Sato, 1986, Actions of tumor necrosis factor on cultured vascular endothelial cells: Morphologic modulation, growth inhibition, and cytotoxicity, J. Natl. Cancer Inst., 76, 1113 Smyth, 1988, The increased anti-tumor effect of immunoconjugates and tumor necrosis factor in vivo, Cancer Res., 48, 3607 Russell, 1990, Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: Parameters in optimization of therapy, Cancer Res., 50, 6028 Marmor, 1979, Interactions of hyperthermia and chemotherapy in animals, Cancer Res., 39, 2269 Pierce, 1970, Differential, normal and malignant cells, Fed. Proc., 29, 1248 Obrist, 1983, Monoclonal antibodies as drug carriers in oncology, Trends Pharmacol. Sci., 165, 375, 10.1016/0165-6147(83)90452-2 Edwards, 1985, Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies, Br. J. Cancer., 51, 149, 10.1038/bjc.1985.24 Poste, 1986, Pathogenesis of metastatic disease: Implications for current therapy and for the development of new therapeutic strategies, Cancer Treat. Rep., 70, 183 Curt, 1984, Drug resistance in cancer, Cancer Treat. Rep., 68, 87 Poste, 1980, The pathogenesis of cancer metastasis., Nature (London), 283, 139, 10.1038/283139a0 Sironi, 1984, Chemotherapy increased antineoplastic effects of antibody-toxin conjugates, Cancer Treat. Rep., 68, 643 Uckun, 1985, Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing poke-weed anti-viral protein, Cancer Res., 45, 69 Webb, 1986, In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: Relevance to immunotherapy of prostate carcinoma, Cancer Immunol. Immunother., 21, 100, 10.1007/BF00199856 D.J. Buchsbaum., L.A. Nelson., and D.E. Hanna., D.A. Vallera., (1986). Human leukemia cell binding and killing by anti-CD5 radioimmunotoxins. In “Proceedings of the American Society for Therapeutic Radiology and Oncology 28th Annual Meeting, Los Angeles.”. Alexander, 1987, Tumor necrosis factor: Synergistic enhancement of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II, Cancer Res., 47, 2403 Greiner, 1987, Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo, Science, 235, 895, 10.1126/science.3580039 Greiner, 1984, Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte γ-interferon treatment, Cancer Res., 44, 3208 Ghose, 1975, Immunochemotherapy of human malignant melanoma with chlorambucil-carrying antibody, Eur. J. Cancer, 11, 321, 10.1016/0014-2964(75)90059-6 Ford, 1983, Localisation and toxicity study of a vindesine-anti-CEA conjugate in patients with advanced cancer, Br. J. Cancer, 47, 35, 10.1038/bjc.1983.4 Melino, 1984, Drug targeting for 7 neuroblastoma patients using human polyclonal antibodies, Protides Biol. Fluids, 32, 413, 10.1016/B978-0-08-031739-7.50104-X Takahashi, 1988, Clinical application of monoclonal antibody-drug conjugates for immunotargeting chemotherapy of colorectal carcinoma, Cancer, 61, 881, 10.1002/1097-0142(19880301)61:5<881::AID-CNCR2820610505>3.0.CO;2-Y Oldham, 1988, Adriamycin custom-tailored immunoconjugates in the treatment of human malignancies, Mol. Biother., 1, 103 Orr, 1989, Phase I trial of mitomycin C immunoconjugates cocktails in human malignancies, Mol. Biother., 1, 229 Oldham, 1989, Individually specified drug immunoconjugates in cancer treatment, Int. J. Biol. Markers, 4, 65, 10.1177/172460088900400202 Schneck, 1989, Phase I studies with a murine monoclonal antibody vinca conjugate (KS1.4-DAVLB) in patients with adenocarcinomas, Antibody Immunoconj. Radiopharm., 2, 93 Elias, 1990, Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunoconjugate in patients with non-small cell lung carcinoma, Cancer Res., 50, 4154 Gould, 1989, Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies, J. Natl. Cancer Inst., 81, 775, 10.1093/jnci/81.10.775 Stewart, 1990, Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer, J. Clin. Oncol., 8, 1941, 10.1200/JCO.1990.8.12.1941 Stewart, 1989, Intraperitoneal radioimmunotherapy for ovarian cancer, Br. J. Obs. Gynaecol., 86, 529, 10.1111/j.1471-0528.1989.tb03251.x Epenetos, 1982, Targeting of iodine-123-labelled tumour associated monoclonal antibodies to ovarian, breast and gastrointestinal tumours, Lancet, 2, 999, 10.1016/S0140-6736(82)90046-0 Hnatowich, 1985, Pharmacokinetics of an indium-III-labelled monoclonal antibody in cancer patients, J. Nucl. Med., 26, 849 Pimm, 1985, The characteristics of blood-bourne radiolabels and the effect of anti-mouse IgG antibodies on localization of radiolabelled monoclonal antibody in cancer patients, J. Nucl. Med., 26, 1011 Rosenblum, 1985, Pharmacokinetics of 111In-labelled anti-p97 monoclonal antibody in patients with metastatic malignant melanoma, Cancer Res., 45, 2382 Colcher, 1987, Quantitative analysis of selective radiolabelled monoclonal antibody localization in metastatic lesions of colorectal cancer patients, Cancer Res., 47, 1185 Ward, 1987, Localization of radioactive conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: Assessment of intravenous and intraperitoneal routes of administration, Cancer Res., 47, 4719 Pimm, 1988, Drug monoclonal antibody conjugates for cancer therapy: Potentials and limitations CRC Crit., Rev. Ther. Drug Carrier Syst., 5, 189 Ballantyne, 1988, Biodistribution of a monoclonal antibody methotrexate conjugate (791T/36-MTX) in patients with colorectal cancer, Int. J. Cancer Suppl., 2, 103, 10.1002/ijc.2910410724 Schneck, 1990, Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas, Clin. Pharmacol. Ther., 47, 36, 10.1038/clpt.1990.5 Pimm, 1984, Quantitative evaluation of the localization of a monoclonal antibody (79IT/36) in human osteogenic sarcoma xenografts, Eur. J. Cancer Clin. Oncol., 20, 515, 10.1016/0277-5379(84)90238-4 Pimm, 1985, Difference in tumour and normal tissue concentrations of iodine and indium-labelled-monoclonal antibody, Eur. J. Nucl. Med., 11, 300, 10.1007/BF00252341 Khaw, 1986, Differences in experimental tumour localization of dual-labelled monoclonal antibody, J. Nucl. Med., 27, 1293 Rogers, 1986, Effect of dose escalation of a monoclonal anti-CEA IgG on tumour localization and tissue distribution in nude mice: Xenografted with human colon carcinoma, Cancer Immunol. Immunother., 23, 107, 10.1007/BF00199815 Rogers, 1986, Dose dependent localisation of a monoclonal F(ab')2 fragment against CEA in the mouse xenograft model, Eur. J. Cancer Clin. Oncol., 22, 709, 10.1016/0277-5379(86)90170-7 Halsall, 1981, Localisation of malignant germ-cell tumours by external scanning after injection of radiolabelled anti-α-fetoprotein, Br. Med. J., 283, 942, 10.1136/bmj.283.6297.942 Abdel-Nabi, 1987, Colorectal carcinoma: Detection with indium-111 anticarcinoembryonic antigen monoclonal antibody, ZCe-025, Radiology, 164, 617, 10.1148/radiology.164.3.3303117 Jaffers, 1983, The human immune response to murine OKT3 monoclonal antibody, Transplant. Proc., 15, 646 Foon, 1984, Effect of monoclonal antibody therapy in patients with chronic lymphocytic leukaemia, Blood, 64, 1085, 10.1182/blood.V64.5.1085.1085 Dillman, 1984, Therapy of chronic lymphocytic leukaemic and cutaneous T-cell lymphoma with T101 monoclonal antibody, J. Clin. Oncol., 2, 881, 10.1200/JCO.1984.2.8.881 Dillman, 1986, Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukaemia and cutaneous T-cell lymphoma, J. Biol. Response Modif., 5, 394 Petersen, 1991, The human immune response to KS1/4-desacetylvinbastine (Ly256787) and KS/4-deacetylvinblasine hydrazide (LY203728) in single and multiple dose clinical studies, Cancer Res., 51, 2286 Frodin, 1988, Clinical effects of monoclonal antibodies (MAb17-1A) in patients with metastatic colorectal carcinoma, Hybridoma, 7, 309, 10.1089/hyb.1988.7.309 Dillman, 1990, Human antimouse and antiglobulin responses to monoclonal antibodies, Antibiot. Immunoconj. Radiopharm., 3, 1 Carson, 1986, Human lymphocyte hybridomas and monoclonal antibodies, Adv. Immunol., 38, 275, 10.1016/S0065-2776(08)60009-7 Riechmann, 1988, Reshaping human antibodies for therapy., Nature (London), 332, 325, 10.1038/332323a0 Brown, 1987, Tumour-specific genetically engineered murine/human chimaeric monoclonal antibody, Cancer Res., 47, 3577 Beidler, 1988, Cloning and high level expression of a chimeric antibody with specificity for human carcinoembryonic antigen, J. Immunol., 141, 4053, 10.4049/jimmunol.141.11.4053 Shaw, 1988, Mouse/human chimeric antibodies to a tumor-associated antigen: Biologic activity of the four human IgG sub-classes, J. Natl. Cancer Inst., 80, 1553, 10.1093/jnci/80.19.1553 Colcher, 1989, Characterisation and biodistribution of recombinant/chimeric constructs of monoclonal antibody B72.3, Cancer Res., 49, 1738 Junghans, 1990, Anti-Tach-H, a humanised antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders, Cancer Res., 50, 1495 Mischak, 1990, Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL, Mol. Biother., 2, 104 Schroff, 1985, Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy, Cancer Res., 45, 879 Ledermann, 1987, Suppression of the anti-mouse antibody response to a monoclonal antitumor antibody in rabbits with cyclosporin A, Br. J. Cancer, 56, 519 Harkonen, 1987, Toxicity and immunogenicity of monoclonal antimelanoma antibodyricin A chain immunotoxin in rats, Cancer Res., 47, 1377 Pai, 1990, Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice, Cancer Res., 50, 7750 Jin, 1991, Suppression of the immune response to immunotoxins with anti-CD4 monoclonal antibodies, J. Immunol., 146, 1806, 10.4049/jimmunol.146.6.1806